← Back to Search
Global Magnitude Of Reported And Unreported Mesothelioma
Eun-Kee Park, K. Takahashi, T. Hoshuyama, T. Cheng, V. Delgermaa, Giang Vinh Le, T. Sorahan
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Background Little is known about the global magnitude of mesothelioma. In particular, many developing countries, including some with extensive historical use of asbestos, do not report mesothelioma. Objectives We estimated the global magnitude of mesothelioma accounting for reported and unreported cases. Methods For all countries with available data on mesothelioma frequency and asbestos use (n = 56), we calculated the 15-year cumulative number of mesotheliomas during 1994–2008 from data available for fewer years and assessed its relationship with levels of cumulative asbestos use during 1920–1970. We used this relationship to predict the number of unreported mesotheliomas in countries for which no information on mesothelioma is available but which have recorded asbestos use (n = 33). Results Within the group of 56 countries with data on mesothelioma occurrence and asbestos use, the 15-year cumulative number of mesothelioma was approximately 174,300. There was a statistically significant positive linear relation between the log-transformed national cumulative mesothelioma numbers and the log-transformed cumulative asbestos use (adjusted R2 = 0.83, p < 0.0001). Extrapolated to the group of 33 countries without reported mesothelioma, a total of approximately 38,900 (95% confidence interval, 36,700–41,100) mesothelioma cases were estimated to have occurred in the 15-year period (1994–2008). Conclusions We estimate conservatively that, globally, one mesothelioma case has been overlooked for every four to five reported cases. Because our estimation is based on asbestos use until 1970, the many countries that increased asbestos use since then should anticipate a higher disease burden in the immediate decades ahead.
This paper references
WHO (World Health Organization). 2010a. World Health Organization Statistical Information System (WHOSIS): Download the Detailed Data Files of the WHO Mortality Database
Worldwide Asbestos Supply and Consumption Trends from 1900 through 2003 Available: http://pubs.usgs. gov/circ
Rl Virta (1298)
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Are Current or Future Mesothelioma Epidemics in Hong Kong the Tragic Legacy of Uncontrolled Use of Asbestos in the Past?
L. A. Tse (2010)
Worldwide Asbestos Supply and Consumption Trends from 1900 through
R L Virta
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis
Ro-Ting Lin (2007)
WHO (World Health Organization). 1977. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death
The asbestos cancer epidemic.
J. LaDou (2004)
World Asbestos Consumption from
R L Virta (2003)
Malignant Mesothelioma in Australia, 1945–2002
J. Leigh (2003)
Malignant mesothelioma mortality--United States, 1999-2005.
K. M. Bang (2009)
Impact of malignant mesothelioma in Taiwan: a 27-year review of population-based cancer registry data.
L. Lee (2010)
Asbestos and mesothelioma: worldwide trends.
L. Kazan-Allen (2005)
A Cross-country Comparative Overview of the Asbestos Situation in Ten Asian Countries
K. Takahashi (2003)
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
Takehiko Murayama (2006)
Recent Mortality from Pleural Mesothelioma, Historical Patterns of Asbestos Use, and Adoption of Bans: A Global Assessment
K. Nishikawa (2008)
Regional Conflict Management in Europe
J. Duffield (2003)
European nations agree to improve environmental health
R. Walgate (2010)
Asbestosis mortality in the USA: facts and predictions
V. C. dos Santos Antao (2008)
WHO (World Health Organization). 2010b. About the WHO Mortality Data Available: http://www.who.int/healthinfo/ statistics/mortdata/en/index.html [accessed 3
Malignant mesothelioma in Australia
A. Musk (2006)
The European mesothelioma epidemic
J. Peto (1999)
World Health Organization Statistical Information System (WHOSIS): Download the Detailed Data Files of the WHO Mortality Database
Recent mortality from pleural
T Hoshuyama (2008)
Global Use of Asbestos and the Incidence of Mesothelioma
A. Tossavainen (2004)
European nations agree to improve
R. 2010. Walgate (2010)
Increased mesothelioma incidence in New Zealand: the asbestos-cancer epidemic has started.
T. Kjellstrom (2000)
Asbestos-related diseases: time for technology sharing
K. Takahashi (2008)
Ecological association between
T Kameda (2007)
Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution.
A. Tossavainen (1997)
Worldwide asbestos supply and consumption trends from 1900 to 2000
R. L. Virta (2003)
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
Malignant Mesothelioma Recognized as Occupational Diseases in Switzerland
M Rüegger (2008)
The global burden of disease due to occupational carcinogens.
T. Driscoll (2005)
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
A. Marinaccio (2007)
Malignant mesothelioma mortality-United States
WHO (World Health Organization). 2006a. Elimination of Asbestos- Related Diseases. Geneva:World Health Organization
Member States of the United Nations
The mesothelioma epidemic
E. Negri (2004)
About the WHO Mortality Data
World Asbestos Consumption from Available: http://minerals.usgs.gov/minerals/pubs/ commodity/asbestos/mis-2007-asbes.pdf [accessed 11
Rl Virta (2003)
International data base.
S. Quick (1984)
Worldwide Asbestos Supply and Consumption
RL 2010.Virta (2006)
Elimination of Asbestos-Related Diseases. Geneva:World Health Organization
This paper is referenced by
Asbestos-related cancers in Brazil.
Benedetto Terracini (2015)
Systemic inflammation in malignant pleural mesothelioma: Is neutrophyl-to-lymphocyte ratio a prognostic index?
Felice Mucilli (2016)
Asbestos-related diseases in mineworkers: a clinicopathological study
Ntombizodwa Ndlovu (2017)
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
A. Baird (2019)
Why some, but not all, countries have banned asbestos
Jinwook Bahk (2013)
Pleural mesothelioma: epidemiological and public health issues. Report from the Second Italian Consensus Conference on Pleural Mesothelioma.
C. Magnani (2013)
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
Respiratory illness in asbestos contaminated sites: the role of environmental exposure
P. Comba (2011)
Awareness of Asbestos and Action Plans for Its Exposure can Help Lives Exposed to Asbestos
Hu-Jang Lee (2013)
Epidemiological surveillance of mesothelioma mortality in Italy.
L Fazzo (2018)
Transnational Dynamics Amid Poor Regulations: Taiwan’s Asbestos Ban Actions and Experiences
Harry Yi-Jui Wu (2017)
MicroRNAs como herramienta potencial para el diagnóstico del mesotelioma pleural maligno
Luis Vicente Gayosso-Gómez (2013)
Estimate of environmental and occupational components in the spatial distribution of malignant mesothelioma incidence in Lombardy (Italy).
Dolores Catelan (2020)
Peritoneal mesothelioma: current status and future directions.
T. Chua (2012)
Asbestos: Resource Recovery and Its Waste Management
Adarsh M. Kumar (2016)
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
An Occupational Legacy: Malignant Mesothelioma Incidence and Mortality in Wisconsin
C. Tomasallo (2018)
[Asbestos, an epidemic that still needs to be controlled].
R. Accinelli (2017)
Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials
B. Mohamed (2017)
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
V. Delgermaa (2011)
Pleural Mesothelioma:Epidemiological and Public Health issues.Report from the Second Italian Consensus Conference on Pleural Mesothelioma
G. Scansetti (2013)
KAT 5 ( Tip 60 ) is a potential therapeutic target in malignant pleural mesothelioma
S. Cregan ()
Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective
E. Algranti (2019)
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
Alice Guazzelli (2017)
Hedgehog Signaling in Malignant Pleural Mesothelioma
Emanuela Felley-Bosco (2015)
The relationship between treatment cost and prognosis of malignant pleural mesothelioma in Turkey
A Guntulu (2019)
A role for strategies in urban climate change adaptation planning: Lessons from London
A. Siders (2017)
Internet of Things in Water Management and Treatment
A. Salam (2020)
Chemotherapy of Malignant Pleural Mesothelioma Induces Both Senescence and Apoptosis
Emanuela Felley-Bosco (2013)
Asbestos-related cancers: the ‘Hidden Killer’ remains a global threat
N. van Zandwijk (2020)
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
S. Hasegawa (2014)
Asbestos use and asbestos‐related diseases in Asia: Past, present and future
G. Le (2011)See more